<DOC>
	<DOCNO>NCT00049517</DOCNO>
	<brief_summary>RATIONALE : Giving combination chemotherapy stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject transplanted stem cell . When healthy stem cell infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . If patient 's stem cell transplant , patient also treat monoclonal antibody , gemtuzumab ozogamicin , kill remain cancer cell deliver cancer-killing substance without harm normal cell . It yet know whether combination chemotherapy effective without gemtuzumab ozogamicin follow stem cell transplant treat acute myeloid leukemia . PURPOSE : This randomized phase III trial study combination chemotherapy , gemtuzumab ozogamicin , stem cell transplant see well work compare combination chemotherapy peripheral stem cell transplant alone treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Monoclonal Antibody Therapy Treating Patients With AML Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To compare overall survival ( OS ) two induction regimen ( standard versus dose intense daunorubicin cytarabine ) patient de novo AML . - To compare disease-free survival ( DFS ) two consolidation regimen . - To compare overall survival two consolidation regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord induction therapy ( standard-dose daunorubicin v high-dose daunorubicin ) . - Induction therapy : Patients randomize 1 2 induction arm . - Standard : Patients receive standard-dose daunorubicin IV 10-15 minute day 1-3 cytarabine IV continuously day 1-7 . - High dose : Patients receive high-dose daunorubicin IV 10-15 minute day 1-3 cytarabine arm I . Patients arm may receive second course induction therapy complete remission ( CR ) achieve first course . The second course administer arm I patient . Patients n't achieve CR 2 course induction therapy remove study . Patients achieve CR induction therapy proceed post-remission therapy EITHER allogeneic transplantation ( study ) OR consolidation therapy autologous transplantation ( study ) , accord risk status donor status . Patients consider intermediate high risk relapse ( unfavorable cytogenetics/high WBC ) suitable relate donor undergo allogeneic transplantation . Patients intermediate-risk cytogenetics , WBC great 100,000/mm^3 , appropriate donor option undergo allogeneic transplantation . - Allogeneic transplantation : Within 1-3 month recovery induction therapy , patient receive busulfan IV every 6 hour day -7 -4 cyclophosphamide IV 4 hour day -3 -2 . Allogeneic bone marrow peripheral blood stem cell ( PBSCs ) infuse day 0 . Patients receive graft-vs-host disease ( GVHD ) prophylaxis comprise cyclosporine IV 1-4 hour begin day -1 orally ( tolerate ) twice daily day 180 . Alternatively , patient may receive tacrolimus IV 24 hour begin day -1 orally twice daily day 180 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Patients meet criterion allogeneic transplantation ( i.e. , favorable risk match related donor ) opt undergo allogeneic transplantation proceed consolidation therapy follow randomization 1 2 autologous transplantation arm . - Consolidation therapy : Beginning 2-8 week recovery induction therapy , patient receive high-dose cytarabine IV 3 hour every 12 hour day 1 , 3 , 5 . A second course administer 3 week blood recovery . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 4 day autologous PBSCs harvest leukapheresis . - Autologous stem cell transplantation : Patients randomize 1 2 autologous transplantation arm . - Arm I : Within 1 month PBSC collection , patient receive condition comprise busulfan IV every 6 hour day -7 -4 cyclophosphamide IV 2 hour day -3 -2 . Patients undergo autologous PBSC transplantation day 0 . Patients receive sargramostim ( GM-CSF ) G-CSF IV SC begin day 0 continue blood count recover . - Arm II ( close accrual 10/4/2007 ) : Within 2-4 week PBSC collection , patient receive gemtuzumab ozogamicin IV 2 hour day 1 GM-CSF SC IV begin day 10 continue blood count recover . Within 2-3 week blood count recovery , patient receive condition undergo autologous PBSC transplantation arm I . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 7 year . ACTUAL ACCRUAL : A total 657 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Morphologically confirm acute myeloid leukemia ( AML ) ( great 20 % blast peripheral blood marrow ) meeting follow criterion : Recurrent cytogenetic translocation ( 8 ; 21 ) ( q22 ; q22 ) Bone marrow eosinophil abnormality inv ( 16 ) ( p13 ; q22 ) ( 16 ; 16 ) ( p13 ; q22 ) 11q23 abnormality Multilineage dysplasia without presence myelodysplastic syndrome ( MDS ) Minimally differentiate AML AML without maturation AML maturation AML otherwise categorize Acute myelomonocytic leukemia Acute monocytic leukemia Acute erythroid leukemia Acute megakaryocytic leukemia Acute basophilic leukemia Patients undergo allogeneic transplantation must sibling donor match define human leukocyte antigen ( HLA ) match haplotype match one locus mismatch haplotype Age 16 60 Eastern Cooperative Oncology Group ( ECOG ) performance status 04 Aspartate aminotransferase ( AST ) less 4 time upper limit normal ( ULN ) Alkaline phosphatase less 4 time ULN Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Left ventricular ejection fraction ( LVEF ) least 45 % postinduction multigated acquisition ( MUGA ) scan Negative pregnancy test Fertile patient must use effective contraception HIV negative Prior hydroxyurea allow Prior corticosteroid allow Recurrent cytogenetic translocation Acute promyelocytic leukemia ( PML ) ( 15 ; 17 ) ( q22 ; q21 ) Variant acute PML ( v ; 17 ) Multilineage dysplasia prior MDS Acute panmyelosis myelofibrosis Blastic transformation chronic myelogenous leukemia Secondary AML ( chemotherapyinduced evolve MDS ) Pregnant nursing Bilirubin great 2.0 mg/dL ( unless relate Gilbert 's syndrome hemolysis ) Significant cardiac disease require active therapy ( e.g. , digoxin , diuretic , antiarrhythmic , antianginal medication ) Prior biologic therapy Prior cytotoxic chemotherapy malignancy Prior radiotherapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>autologous transplantation</keyword>
	<keyword>gemtuzumab ozogamicin</keyword>
</DOC>